@27082yk: 2026.9.26 #みるくシャカレボシャカレボ福岡楽しかった🎶

♡

Open In TikTok:

Region: JP

Sunday 27 September 2026 05:07:19 GMT

9472

978

4

19

Music

Download

No Watermark .mp4 (7.5MB) No Watermark(HD) .mp4 (6.14MB) Watermark .mp4 (0MB) Music .mp3

Comments

舜子. :

主さんに確定ファンサしてません！？

2026-09-27 08:46:53

10

Mia🎀🫧 :

え！めちゃ近いですね！！

2026-09-27 11:42:39

2

あι⇂💧🩷ྀི🤍ᩚ❤️ྀི💧 :

行きたかったですね😭

2026-09-27 09:58:23

0

あι⇂💧🩷ྀི🤍ᩚ❤️ྀི💧 :

楽しそうですね！

2026-09-27 09:58:08

0

To see more videos from user @27082yk, please go to the Tikwm homepage.

Other Videos

Food Recalls

The World Grand Prix is such a vibe | #lightningmcqueen #pixarcars #carsmovie #edit #fyp

The World Grand Prix is such a vibe | #lightningmcqueen #pixarcars #carsmovie #edit #fyp

#سوبر_تشارج #الامواه_الحباب #العمق #مجرد________ذووووووق🎶🎵💞 #اكسبلور

#سوبر_تشارج #الامواه_الحباب #العمق #مجرد________ذووووووق🎶🎵💞 #اكسبلور

🟦 GLAUCOMA MANAGEMENT — TYPES • PATHOPHYSIOLOGY • RISK FACTORS • COMPLICATIONS • TREATMENT 👁️ A comprehensive clinical learning note for Optometry & Ophthalmology students Glaucoma is not simply “high eye pressure.” It is a group of progressive optic neuropathies characterized by structural damage to the optic nerve head and corresponding functional visual-field abnormalities. Although elevated intraocular pressure (IOP) is the most important modifiable risk factor, glaucomatous damage can occur even when IOP is within the statistically normal range. 🎯 PRIMARY GOAL OF MANAGEMENT The fundamental objective is: Preserve the patient's remaining visual function and quality of life by preventing or slowing further glaucomatous optic neuropathy. Currently, established treatment strategies primarily work by lowering IOP. Treatment cannot reliably restore established glaucomatous optic nerve damage or lost visual field, which makes early detection and longitudinal monitoring essential. ━━━━━━━━━━━━━━━━━━ 🔬 1. PATHOPHYSIOLOGY OF GLAUCOMA ━━━━━━━━━━━━━━━━━━ Normal aqueous humour is produced by the ciliary body → passes through the posterior chamber → pupil → anterior chamber → exits mainly through the trabecular meshwork and Schlemm's canal. When aqueous humour outflow is impaired: ↓ Aqueous outflow ⬇️ ↑ IOP / altered biomechanical stress ⬇️ Stress on the optic nerve head ⬇️ Retinal ganglion cell and axonal injury ⬇️ RNFL thinning + optic-disc cupping ⬇️ Progressive visual-field loss ⬇️ Advanced disease → severe visual impairment/blindness However, glaucoma is more complex than pressure alone. Susceptibility of the optic nerve, vascular factors, age, corneal thickness, genetics and other ocular/systemic factors influence the relationship between IOP and damage. ━━━━━━━━━━━━━━━━━━ 🧠 2. IMPORTANT FACTORS INFLUENCING GLAUCOMATOUS DAMAGE ━━━━━━━━━━━━━━━━━━ 🔴 Major risk/progression factors • Elevated IOP • Increasing age • Positive family history • Previous or current glaucoma in the fellow eye • Thin central corneal thickness (CCT) • High myopia in relevant glaucoma phenotypes • Anatomically narrow/occludable angles • Certain genetic predispositions • Optic-nerve susceptibility • Vascular/systemic factors in selected patients • Long-term corticosteroid exposure • Ocular trauma • Uveitis and other secondary ocular diseases Importantly, CCT is not merely a correction factor for IOP; it is also an independent risk marker in glaucoma assessment. NICE recommends considering IOP, CCT, family history and life expectancy when assessing the future risk associated with ocular hypertension. ━━━━━━━━━━━━━━━━━━ 👁️ 3. MAJOR TYPES OF GLAUCOMA & MANAGEMENT ━━━━━━━━━━━━━━━━━━ 🟢 A. PRIMARY OPEN-ANGLE GLAUCOMA (POAG) The anterior chamber angle remains anatomically open, but aqueous humour outflow through the conventional drainage pathway is dysfunctional. Clinical characteristics: • Usually chronic and progressive • Often asymptomatic in early stages • Optic-disc/RNFL damage • Characteristic glaucomatous visual-field defects • IOP may be elevated, but does not have to be MANAGEMENT 1️⃣ IOP-lowering medication Common pharmacological classes include: 🔹 Prostaglandin analogues Examples: latanoprost, travoprost, bimatoprost, tafluprost → Increase uveoscleral outflow. 🔹 β-blockers Examples: timolol, betaxolol → Reduce aqueous humour production. ⚠️ Important systemic considerations include asthma/COPD, bradycardia and certain cardiac conduction disorders. 🔹 Topical carbonic anhydrase inhibitors Examples: dorzolamide, brinzolamide → Reduce aqueous production. 🔹 α₂-adrenergic agonists Example: brimonidine → Reduce aqueous production and may increase uveoscleral outflow. 🔹 Rho-kinase (ROCK) inhibitors Example: netarsudil → Increase trabecular outflow and influence episcleral venous resistance. 🔹 Fixed-combination preparations Can reduce the number of separate instillations and may improve treatment convenience.

🟦 GLAUCOMA MANAGEMENT — TYPES • PATHOPHYSIOLOGY • RISK FACTORS • COMPLICATIONS • TREATMENT 👁️ A comprehensive clinical learning note for Optometry & Ophthalmology students Glaucoma is not simply “high eye pressure.” It is a group of progressive optic neuropathies characterized by structural damage to the optic nerve head and corresponding functional visual-field abnormalities. Although elevated intraocular pressure (IOP) is the most important modifiable risk factor, glaucomatous damage can occur even when IOP is within the statistically normal range. 🎯 PRIMARY GOAL OF MANAGEMENT The fundamental objective is: Preserve the patient's remaining visual function and quality of life by preventing or slowing further glaucomatous optic neuropathy. Currently, established treatment strategies primarily work by lowering IOP. Treatment cannot reliably restore established glaucomatous optic nerve damage or lost visual field, which makes early detection and longitudinal monitoring essential. ━━━━━━━━━━━━━━━━━━ 🔬 1. PATHOPHYSIOLOGY OF GLAUCOMA ━━━━━━━━━━━━━━━━━━ Normal aqueous humour is produced by the ciliary body → passes through the posterior chamber → pupil → anterior chamber → exits mainly through the trabecular meshwork and Schlemm's canal. When aqueous humour outflow is impaired: ↓ Aqueous outflow ⬇️ ↑ IOP / altered biomechanical stress ⬇️ Stress on the optic nerve head ⬇️ Retinal ganglion cell and axonal injury ⬇️ RNFL thinning + optic-disc cupping ⬇️ Progressive visual-field loss ⬇️ Advanced disease → severe visual impairment/blindness However, glaucoma is more complex than pressure alone. Susceptibility of the optic nerve, vascular factors, age, corneal thickness, genetics and other ocular/systemic factors influence the relationship between IOP and damage. ━━━━━━━━━━━━━━━━━━ 🧠 2. IMPORTANT FACTORS INFLUENCING GLAUCOMATOUS DAMAGE ━━━━━━━━━━━━━━━━━━ 🔴 Major risk/progression factors • Elevated IOP • Increasing age • Positive family history • Previous or current glaucoma in the fellow eye • Thin central corneal thickness (CCT) • High myopia in relevant glaucoma phenotypes • Anatomically narrow/occludable angles • Certain genetic predispositions • Optic-nerve susceptibility • Vascular/systemic factors in selected patients • Long-term corticosteroid exposure • Ocular trauma • Uveitis and other secondary ocular diseases Importantly, CCT is not merely a correction factor for IOP; it is also an independent risk marker in glaucoma assessment. NICE recommends considering IOP, CCT, family history and life expectancy when assessing the future risk associated with ocular hypertension. ━━━━━━━━━━━━━━━━━━ 👁️ 3. MAJOR TYPES OF GLAUCOMA & MANAGEMENT ━━━━━━━━━━━━━━━━━━ 🟢 A. PRIMARY OPEN-ANGLE GLAUCOMA (POAG) The anterior chamber angle remains anatomically open, but aqueous humour outflow through the conventional drainage pathway is dysfunctional. Clinical characteristics: • Usually chronic and progressive • Often asymptomatic in early stages • Optic-disc/RNFL damage • Characteristic glaucomatous visual-field defects • IOP may be elevated, but does not have to be MANAGEMENT 1️⃣ IOP-lowering medication Common pharmacological classes include: 🔹 Prostaglandin analogues Examples: latanoprost, travoprost, bimatoprost, tafluprost → Increase uveoscleral outflow. 🔹 β-blockers Examples: timolol, betaxolol → Reduce aqueous humour production. ⚠️ Important systemic considerations include asthma/COPD, bradycardia and certain cardiac conduction disorders. 🔹 Topical carbonic anhydrase inhibitors Examples: dorzolamide, brinzolamide → Reduce aqueous production. 🔹 α₂-adrenergic agonists Example: brimonidine → Reduce aqueous production and may increase uveoscleral outflow. 🔹 Rho-kinase (ROCK) inhibitors Example: netarsudil → Increase trabecular outflow and influence episcleral venous resistance. 🔹 Fixed-combination preparations Can reduce the number of separate instillations and may improve treatment convenience.

#CapCut

#ghanatiktok🇬🇭 #

#ghanatiktok🇬🇭 #

About

Robot
API

Legal

Privacy Policy